Prix ​​Galien Italia 2022 to Abbott for glucose measurement system

Abbott won the prestigious Prix Galien Italia 2022 in the ‘Medicine and digital therapies’ category for the new generation FreeStyle Libre 3 continuous glucose monitoring system (Cmg). latest and most innovative sensor technology and has been designed with people with diabetes with more complex management needs in mind. The Prix Galien is considered the ‘Nobel Prize’ for innovation in biopharmaceutical research and recognizes excellence in medical and scientific research and innovation. “Winning the Prix Galien Italia represents an important recognition of our commitment to designing accurate and accessible technology, which is truly changing the lives of millions of people with diabetes – declares Luigi Russo, General Manager of Abbott Diabetes Care Italy -. motivates even more to continue to innovate and offer more personalized and precise treatments, create a shared communication channel between people with diabetes and the doctor and allow greater self-control of their health “. According to the independent scientific board that awarded the award , “FreeStyle Libre 3 – reports the note – is an innovative continuous glucose monitoring system for adults and children with diabetes mellitus which, due to its technological characteristics, can have a potentially very significant social impact, considering the importance of the population of reference and complexity of the management of this pathology.The system has a greater measurement accuracy, compared to other similar systems, does not require calibration and guarantees the utmost discretion in monitoring, thus making patients more active towards their pathology, a fundamental premise for improving health outcomes “. An increasing number of evidence has demonstrated the effectiveness of the FreeStyle Libre system in reducing acute diabetes-related events and hospitalizations in people with type 1 and type 2 diabetes on multi-injection insulin therapy, the note reads again. Furthermore, a recent study just published in the ‘Journal of Diabetes Technology & Therapeutics’ showed that the system can help reduce the serious complications of diabetes even in people with type 2 diabetes on once-a-day insulin therapy (basal insulin), with a 67% reduction in hospitalizations, 75% in hospitalizations for diabetic ketoacidosis and 44% in hospitalizations for severe hypoglycemia. The Prix Galien is an initiative born in France in the 70s to enhance innovation. The award takes place in many countries with various declinations and is coordinated by the Galien Foundation of New York. In 2019 the previous system, FreeStyle Libre 2, had also obtained the prestigious recognition in Italy in the Medical Devices / Technologies category. The system awarded this year – reads the note – is the latest addition to the FreeStyle Libre portfolio. With its launch this summer in Italy, Abbott has expanded the range of sensor glucose monitoring solutions available in people with type 1 and type 2 diabetes with more complex diabetes management needs and who require a CGM device on time. real, such as people with type 1 diabetes. The technology of the device – still reports the note – provides continuous glucose readings, automatically sent minute-by-minute via Bluetooth to smartphones. The small, slim and discreet sensor (thinner than two overlapping 5-cent coins) is simple to apply to the back of the arm for up to 14 days with a dedicated applicator, eliminating the need for painful finger pricks and has a clinical accuracy level (Madr) of less than 8%. In addition to the sensor, the system includes the FreeStyle Libre 3 app, designed to allow users to receive and view glucose data, glucose history and trend arrows in real time. Users can also set optional alarms and notifications that warn when set glucose levels are exceeded. The app integrates with the digital ecosystem that allows users to share glucose data with their doctor and caregivers.